Carlsmed (NASDAQ:CARL) Shares Climb 0.5% – What’s Next?

Carlsmed, Inc. (NASDAQ:CARL)’s share price traded up 0.5% during trading on Monday. The stock traded as high as $15.66 and last traded at $15.02. Approximately 93,674 shares changed hands during trading, an increase of 10% from the average session volume of 84,905 shares. The stock had previously closed at $14.95.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on CARL. BTIG Research upped their target price on Carlsmed from $23.00 to $24.00 and gave the company a “buy” rating in a report on Monday, October 12th. Weiss Ratings upgraded Carlsmed from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Truist Financial boosted their price objective on Carlsmed from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Finally, Wall Street Zen upgraded Carlsmed from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.50.

Carlsmed Stock Up 11.7%

The company’s 50 day moving average price is $14.98 and its 200-day moving average price is $12.47. The company has a debt-to-equity ratio of 0.18, a quick ratio of 8.66 and a current ratio of 8.84.

Carlsmed (NASDAQ:CARL) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.01. Carlsmed had a negative return on equity of 38.06% and a negative net margin of 57.42%. The business had revenue of $18.94 million during the quarter. Equities analysts forecast that Carlsmed, Inc. will post -1.50 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Jupiter Topco LLC bought a new position in Carlsmed during the second quarter worth about $12,992,000. Janus Henderson Group PLC raised its position in shares of Carlsmed by 7.6% in the first quarter. Janus Henderson Group PLC now owns 1,227,452 shares of the company’s stock valued at $11,108,000 after purchasing an additional 86,834 shares during the period. Parkman Healthcare Partners LLC bought a new stake in shares of Carlsmed in the second quarter valued at approximately $6,200,000. BlackRock Inc. purchased a new stake in shares of Carlsmed during the 2nd quarter valued at approximately $5,528,000. Finally, KCM Capital Inc purchased a new stake in shares of Carlsmed during the 1st quarter valued at approximately $1,810,000.

About Carlsmed

Carlsmed, Inc is a medical technology company focused on personalized solutions for spine surgery. The company combines patient-specific planning, advanced imaging, software and additive manufacturing to develop implants designed to address the anatomical needs of individual patients.

Its products include the aprevo® patient-specific interbody implant system, which is designed for use in spinal fusion procedures. Carlsmed’s technology is intended to support surgeons in planning procedures and selecting or creating implants that may help restore spinal alignment and improve surgical precision.

Carlsmed serves the spine-care market through relationships with spine surgeons, hospitals and other healthcare providers.